Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
13 11 2019
Historique:
received: 25 07 2019
accepted: 27 09 2019
entrez: 15 11 2019
pubmed: 15 11 2019
medline: 28 4 2020
Statut: epublish

Résumé

Sepsis is an increasingly significant challenge throughout the world as one of the major causes of patient morbidity and mortality. Central to the host immunologic response to sepsis is the increase in circulating myeloid-derived suppressor cells (MDSCs), which have been demonstrated to be present and independently associated with poor long-term clinical outcomes. MDSCs are plastic cells and potentially modifiable, particularly through epigenetic interventions. The objective of this study was to determine how the suppressive phenotype of MDSCs evolves after sepsis in surgical ICU patients, as well as to identify epigenetic differences in MDSCs that may explain these changes. Circulating MDSCs from 267 survivors of surgical sepsis were phenotyped at various intervals over 6 weeks, and highly enriched MDSCs from 23 of these samples were co-cultured with CD3/CD28-stimulated autologous T cells. microRNA expression from enriched MDSCs was also identified. We observed that MDSC numbers remain significantly elevated in hospitalized sepsis survivors for at least 6 weeks after their infection. However, only MDSCs obtained at and beyond 14 days post-sepsis significantly suppressed T lymphocyte proliferation and IL-2 production. These same MDSCs displayed unique epigenetic (miRNA) expression patterns compared to earlier time points. We conclude that in sepsis survivors, immature myeloid cell numbers are increased but the immune suppressive function specific to MDSCs develops over time, and this is associated with a specific epigenome. These findings may explain the chronic and persistent immune suppression seen in these subjects.

Sections du résumé

BACKGROUND
Sepsis is an increasingly significant challenge throughout the world as one of the major causes of patient morbidity and mortality. Central to the host immunologic response to sepsis is the increase in circulating myeloid-derived suppressor cells (MDSCs), which have been demonstrated to be present and independently associated with poor long-term clinical outcomes. MDSCs are plastic cells and potentially modifiable, particularly through epigenetic interventions. The objective of this study was to determine how the suppressive phenotype of MDSCs evolves after sepsis in surgical ICU patients, as well as to identify epigenetic differences in MDSCs that may explain these changes.
METHODS
Circulating MDSCs from 267 survivors of surgical sepsis were phenotyped at various intervals over 6 weeks, and highly enriched MDSCs from 23 of these samples were co-cultured with CD3/CD28-stimulated autologous T cells. microRNA expression from enriched MDSCs was also identified.
RESULTS
We observed that MDSC numbers remain significantly elevated in hospitalized sepsis survivors for at least 6 weeks after their infection. However, only MDSCs obtained at and beyond 14 days post-sepsis significantly suppressed T lymphocyte proliferation and IL-2 production. These same MDSCs displayed unique epigenetic (miRNA) expression patterns compared to earlier time points.
CONCLUSIONS
We conclude that in sepsis survivors, immature myeloid cell numbers are increased but the immune suppressive function specific to MDSCs develops over time, and this is associated with a specific epigenome. These findings may explain the chronic and persistent immune suppression seen in these subjects.

Identifiants

pubmed: 31722736
doi: 10.1186/s13054-019-2628-x
pii: 10.1186/s13054-019-2628-x
pmc: PMC6854728
doi:

Substances chimiques

MicroRNAs 0

Banques de données

ClinicalTrials.gov
['NCT02276417']

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

355

Subventions

Organisme : NIGMS NIH HHS
ID : P50 GM-111152
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008721
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG028740
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM-113945
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM-008721
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM-104481
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM-040586
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM105893
Pays : United States

Références

Crit Care Med. 2019 Aug;47(8):e700-e709
pubmed: 31149961
J Trauma Acute Care Surg. 2014 Feb;76(2):311-7; discussion 318-9
pubmed: 24458039
Nat Immunol. 2010 Feb;11(2):141-7
pubmed: 19946272
J Exp Med. 2007 Jun 11;204(6):1463-74
pubmed: 17548519
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
J Exp Med. 2006 Nov 27;203(12):2691-702
pubmed: 17101732
Front Immunol. 2018 Jul 02;9:1511
pubmed: 30013565
Innate Immun. 2014 Apr;20(3):227-38
pubmed: 23757323
Crit Care Med. 2013 Dec;41(12):2770-2
pubmed: 23989175
Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787
pubmed: 29617574
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care Med. 2001 Jul;29(7 Suppl):S109-16
pubmed: 11445744
Am J Respir Crit Care Med. 2018 Mar 1;197(5):677-678
pubmed: 28984471
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
J Biol Chem. 1988 Feb 5;263(4):1709-12
pubmed: 2828349
Clin Cancer Res. 2015 Sep 15;21(18):4073-4085
pubmed: 25922428
ILAR J. 2017 Jul 1;58(1):90-105
pubmed: 28444204
J Leukoc Biol. 2014 Nov;96(5):685-93
pubmed: 24929004
Intensive Care Med. 2012 Jun;38(6):928-30
pubmed: 22552587
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17111-6
pubmed: 21969559
Front Immunol. 2019 Jun 18;10:1363
pubmed: 31275313
J Immunol. 2012 May 1;188(9):4226-34
pubmed: 22474024
J Trauma Acute Care Surg. 2018 Feb;84(2):342-349
pubmed: 29251709
Sci Rep. 2018 Feb 28;8(1):3753
pubmed: 29491381
BMJ Open. 2017 Aug 1;7(7):e015136
pubmed: 28765125
J Trauma Acute Care Surg. 2012 Jun;72(6):1491-501
pubmed: 22695412
Oncotarget. 2016 Aug 30;7(35):57452-57463
pubmed: 27458169
Front Immunol. 2017 Dec 21;8:1870
pubmed: 29312346
J Leukoc Biol. 2015 Dec;98(6):945-52
pubmed: 26034205
Crit Care Med. 2019 Apr;47(4):566-573
pubmed: 30664526
Am J Cancer Res. 2017 Jan 01;7(1):41-52
pubmed: 28123846
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Shock. 2018 Mar;49(3):249-258
pubmed: 28885387
Cancer Immunol Immunother. 2012 Aug;61(8):1155-67
pubmed: 22692756
PLoS One. 2010 Nov 23;5(11):e14088
pubmed: 21124895
Infect Immun. 2012 Jun;80(6):2026-34
pubmed: 22451518
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Infect Immun. 2014 Sep;82(9):3816-25
pubmed: 24980967
JCI Insight. 2018 Mar 8;3(5):
pubmed: 29515037
Mediators Inflamm. 2017;2017:7521701
pubmed: 28337051
Curr Opin Immunol. 2010 Apr;22(2):238-44
pubmed: 20171075
Surgery. 2018 Mar;163(3):627-632
pubmed: 29336814
Ann Surg. 2019 Sep;270(3):502-510
pubmed: 31356275
Ageing Res Rev. 2018 Dec;48:1-10
pubmed: 30248408
Ann Surg. 2017 Apr;265(4):827-834
pubmed: 27163951
Blood. 2009 May 7;113(19):4720-8
pubmed: 19278956
Front Immunol. 2018 Apr 04;9:595
pubmed: 29670613
Elife. 2015 Aug 12;4:null
pubmed: 26267216
Mol Med. 2011 Mar-Apr;17(3-4):281-92
pubmed: 21085745
Crit Care Med. 2017 Feb;45(2):253-262
pubmed: 27632674
Vaccines (Basel). 2016 Nov 03;4(4):
pubmed: 27827871
Trauma Surg Acute Care Open. 2017 Sep 7;2(1):e000088
pubmed: 29766091
Am J Surg. 2010 Dec;200(6):776-82; discussion 782
pubmed: 21146020
Crit Care Med. 2019 May;47(5):632-642
pubmed: 30747773
Am J Respir Crit Care Med. 2017 Aug 1;196(3):315-327
pubmed: 28146645
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Front Immunol. 2019 Feb 27;10:327
pubmed: 30873175
J Immunol. 2014 Jun 15;192(12):6111-9
pubmed: 24829407
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Crit Care Med. 2015 Apr;43(4):738-46
pubmed: 25746745
J Exp Med. 2010 Mar 15;207(3):475-89
pubmed: 20212066
Front Cell Infect Microbiol. 2018 Sep 13;8:321
pubmed: 30271756
Crit Care Med. 2016 Aug;44(8):1461-7
pubmed: 26992066
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
Nature. 2010 Sep 2;467(7311):86-90
pubmed: 20693987
Cancer Genet. 2015 May;208(5):225-9
pubmed: 25686674

Auteurs

McKenzie K Hollen (MK)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Julie A Stortz (JA)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Dijoia Darden (D)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Marvin L Dirain (ML)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Dina C Nacionales (DC)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Russell B Hawkins (RB)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Michael C Cox (MC)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Maria-Cecilia Lopez (MC)

Department of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, FL, USA.

Jaimar C Rincon (JC)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Ricardo Ungaro (R)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Zhongkai Wang (Z)

Department of Biostatistics, University of Florida College of Medicine, Gainesville, FL, USA.

Quran Wu (Q)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Babette Brumback (B)

Department of Biostatistics, University of Florida College of Medicine, Gainesville, FL, USA.

Marie-Pierre L Gauthier (ML)

Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, FL, USA.

Michael Kladde (M)

Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, FL, USA.

Christiaan Leeuwenburgh (C)

Department of Aging and Geriatric Research, University of Florida College of Medicine, Gainesville, FL, USA.

Mark Segal (M)

Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA.

Azra Bihorac (A)

Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA.

Scott Brakenridge (S)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Frederick A Moore (FA)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Henry V Baker (HV)

Department of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, FL, USA.

Alicia M Mohr (AM)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Lyle L Moldawer (LL)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA.

Philip A Efron (PA)

Department of Surgery, Shands Hospital, University of Florida College of Medicine, Room 6116, 1600 SW Archer Road, Gainesville, FL, 32610-0019, USA. philip.efron@surgery.ufl.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH